AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Summary
•
Modular Medical’s 26.9% intraday freefall has triggered urgent scrutiny. The stock’s collapse follows a $4.68 million public offering priced at $0.38 per share, below its current $0.3299 level. With technical indicators flashing bearish signals and sector peers like Medtronic (MDT) rising 0.66%, the selloff reflects a mix of capital-raising pressure and deteriorating market sentiment.
Capital-Raising Pressure and Technical Exhaustion Fuel MODD’s Freefall
Modular Medical’s 26.9% intraday plunge is directly tied to its $4.68 million public offering, which priced 12.17 million shares at $0.38 each—well below the $0.4516 previous close. The offering, announced December 9, created immediate downward pressure as the market priced in dilution risks. Compounding this, technical indicators confirm bearish exhaustion: the stock trades below its 30D ($0.4754), 100D ($0.6265), and 200D ($0.7533) moving averages, while RSI (38.83) and MACD (-0.0284) signal a breakdown. The 52-week low at $0.28 now looms as a critical threshold.
Healthcare Sector Resilient as Medtronic Gains Outpace MODD's Slide
While
Bearish Technical Setup: Short-Term Plays and ETF Exposure
• 200-day average: $0.7533 (far below current price)
• RSI: 38.83 (oversold)
• MACD: -0.0284 (bearish)
• Bollinger Bands: $0.3652 (lower band) near critical support
MODD’s technical profile demands a short-term bearish bias. Key levels to monitor: the 52-week low at $0.28 and the 30D MA at $0.4754. While RSI suggests a potential rebound, the MACD and moving averages favor continuation of the downtrend. With no options chain available, consider leveraged ETFs like XLV (healthcare sector) for directional exposure. Aggressive traders may short MODD if it breaks below $0.3017, but liquidity risks remain high due to low turnover.
Backtest Modular Medical Stock Performance
Modular Medical (MODD) has experienced a significant intraday plunge of 27% from February 2022 to the present date. During this period, the stock's performance has been marked by extreme volatility and bearish technical indicators. The 2022 price of $6.00 per unit in a public offering seems distant, with recent trading below key moving averages like the 30-day ($0.4754), 100-day ($0.6265), and 200-day ($0.7533) averages. The Relative Strength Index (RSI) is at 38.83, indicating oversold conditions. The stock's 3.55% turnover rate is significantly below its 21-month average, suggesting liquidity challenges with sellers dominating the trade. The recent 52-week low of $0.28 is a critical support level, and the stock's performance is closely watched for signs of reversal or further declines. The broader healthcare sector has shown mixed performance, with some peers like Medtronic (MDT) experiencing muted gains, which may indicate that the selloff in MODD is primarily driven by internal technical factors rather than broader industry trends.In conclusion, the performance of MODD after the -27% intraday plunge from 2022 to now has been characterized by sustained bearish pressure, technical exhaustion, and limited sector support. The stock remains in an oversold state, and its future trajectory will likely depend on the emergence of catalysts that could reverse the current downtrend.
Critical Support Test Looms: Act Now or Miss the Exit
MODD’s 26.9% drop signals a high-risk technical breakdown, with the 52-week low at $0.28 as the next critical threshold. While RSI hints at a potential bounce, the long-term bearish trend and negative MACD suggest further declines. Medtronic’s 0.66% gain highlights sector resilience, but MODD’s liquidity crunch demands caution. Immediate action: short MODD if it breaks below $0.3017 or buy a put if the stock stabilizes near $0.3442. Watch for a breakdown below $0.28 to confirm the bear case.
TickerSnipe provides professional intraday stock analysis using technical tools to help you understand market trends and seize short-term trading opportunities.

Dec.12 2025

Dec.12 2025

Dec.12 2025

Dec.12 2025

Dec.12 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet